LXR ligand testing method

Details LXR ligand testing method LXR ligand testing method

2011-08-02

2011-08-02

Pak, Michael (Department: 1646)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving cholesterol

Reexamination Certificate

active

07989179

ABSTRACT:
A method of easily measuring whether or not an LXR ligand has the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration in a mammal by using the binding activity between LXR and a coactivator, and a method of identifying LXR ligands that do not have the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration by using the binding activity between LXR and a coactivator.

REFERENCES:
patent: 6090836 (2000-07-01), Adams et al.
patent: 6316503 (2001-11-01), Li et al.
patent: 6828446 (2004-12-01), Chandrakumar et al.
patent: 7112606 (2006-09-01), Jiao et al.
patent: 7247748 (2007-07-01), Thompson et al.
patent: 7250283 (2007-07-01), Spiegelman et al.
patent: 2002/0037514 (2002-03-01), Klein et al.
patent: 2003/0073614 (2003-04-01), Schulman et al.
patent: 2003/0207898 (2003-11-01), Chandrakumar et al.
patent: 2003/0220339 (2003-11-01), Jiao et al.
patent: 2003/0228607 (2003-12-01), Wagner et al.
patent: 2004/0072868 (2004-04-01), Collins et al.
patent: 2004/0110947 (2004-06-01), Chandrakumar et al.
patent: 2004/0254362 (2004-12-01), Spiegelman et al.
patent: 2005/0014807 (2005-01-01), Adams et al.
patent: 2005/0107444 (2005-05-01), Thompson et al.
patent: 2005/0113580 (2005-05-01), Thompson et al.
patent: 2005/0131014 (2005-06-01), Collini et al.
patent: 2005/0261319 (2005-11-01), Deuschle et al.
patent: 2005/0282908 (2005-12-01), Collins et al.
patent: 2006/0041164 (2006-02-01), Thompson et al.
patent: 2006/0058351 (2006-03-01), Diaz et al.
patent: 2006/0094733 (2006-05-01), Boggs et al.
patent: 2006/0189663 (2006-08-01), Holm
patent: 2006/0270718 (2006-11-01), Jiao et al.
patent: 1 407 774 (2004-04-01), None
patent: WO 99/18124 (1999-04-01), None
patent: WO 01/73434 (2001-10-01), None
patent: WO 01/82917 (2001-11-01), None
patent: WO 02/077229 (2002-10-01), None
patent: WO 03/004613 (2003-01-01), None
patent: WO 03/090869 (2003-11-01), None
patent: WO 03/106435 (2003-12-01), None
patent: WO 2005/019264 (2005-03-01), None
patent: WO 2006/004030 (2006-01-01), None
patent: WO 2006/046593 (2006-05-01), None
English-language International Preliminary Report on Patentability and Written Opinion of the International Searching Authority, dated Jan. 9, 2008 for International application PCT/US2006/024945 filed Jun. 26, 2006; Applicants: Daiichi Sankyo Company Limited.
Bowman Miao et al., “Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator,”Journal of Lipid Research, vol. 45, 2004, pp. 1410-1417.
Patricia D. Pelton et al., “Nuclear Receptors as Potential Targets for Modulating Reverse Cholesterol Transport,”Current Topics in Medicinal Chemistry, Bentham Science Publishers, Hilversum, NL, vol. 5, No. 3, Jan. 1, 2005, pp. 265 to 281.
Deepak S. Lala, “The Liver X Receptors,”Current Opinion in Investigational Drugs, Pharmapress, US, vol. 6, No. 9, Jan. 1, 2005, pp. 934 to 943.
Bodzioch et al., “The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease,”Nature Genetics, (1999), vol. 22, 347-351.
Laffitte et al., “Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue,”Proc. Natl. Acad. Sci. USA, (2003), vol. 100, No. 9, 5419-5424.
Ijpenberg et al., “In vivo activation of PPAR target genes by RXR homodimers,”EMBO J., (2004), vol. 23, No. 10, 2083-2091.
Kim et al., “Activating Signal Cointegrator 2 Required for Liver Lipid Metbolism Mediated by Liver X Receptors in Mice,”Mol. Cell. Biol., (2003), vol. 23, No. 10, 3583-3592.
Huuskonen et al., “Role of p160 Coactivator Complex in the Activation of Liver X Receptor,”Arterioscler. Thromb. Vasc. Biol., (2004), 24, 703-708.
Kawajiri et al., “Role of the LXXLL-Motif and Activation Function 2 Domain in Subcellular Localization of Dax-1 (Dosage-Sensitive Sex Reversal-Adrenal Hypoplasia Congenita Critical Region on the X Chromosome, Gene 1),”Mol. Endocrinol., (2003), 17, 994-1004.
Zhou et al., “PNRC: A Proline-Rich Nuclear Receptor Coregulatory Protein That Modulates Transcriptional Activation of Multiple Nuclear Receptors Including Orphan Receptors SF1 (Steroidogenic Factor 1) and ERRα 1 (Estrogen Related Receptor α-1),”Mol. Endocrinol., (2000), 14(7), 986-998.
Pogenberg et al., “Characterization of the Interaction between Retinoic Acid Receptor/Retinoid X Receptor (RAR/RXR) Heterodimers and Transcriptional Coactivators through Structural and Fluorescence Anisotropy Studies,”J. Biol. Chem., (2005), vol. 280, No. 2, 1625-1633.
Waters et al., “Structural Diversity in p160/CREB-binding Protein Coactivator Complexes,”J. Biol. Chem., (2006), vol. 281, No. 21, 14787-14795.
Bennett et al., “Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis,”Recent Patents on Cardiovascular Drug Discovery, (2006), 1, 21-46.
Willy et al., “LXR, a nuclear receptor that defines a distinct retinoid response pathway,”Genes&Dev., (1995), 9(9), 1033-1045.

Affiliated with

Also associated with

Rating

LXR ligand testing method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LXR ligand testing method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LXR ligand testing method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2702244